Evidence map›Paper›PMID 35014944›Full record

ArticleBioengineered2022

LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells.

Deli Tan, Gang Li, Peng Zhang, Chao Peng, Bo He

RetractedOpen access · goldAbstract readVideo-Audio MediaRetracted Publication
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. The crucial roles of long noncoding RNA SNHGs in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Deli TanDepartment of Thoracic Surgery, Chongqing Ninth People's Hospital, Chongqing, China.
Gang LiDepartment of Thoracic Surgery, Chongqing Ninth People's Hospital, Chongqing, China.
Peng ZhangDepartment of Thoracic Surgery, Chongqing Ninth People's Hospital, Chongqing, China.
Chao PengDepartment of Thoracic Surgery, Chongqing Ninth People's Hospital, Chongqing, China.
Bo HeDepartment of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China.ORCID 0000-0003-3773-6516
Army Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small-cell lung cancer (NSCLC) is defined as the most universally diagnosed class of lung cancer. Cisplatin (DDP) is an effective drug for NSCLC, but tumors are prone to drug resistance. The current study set out to evaluate the regulatory effect of long non-coding RNA (lncRNA) small nucleolar RNA host gene 12 (SNHG12) in extracellular vesicles (EVs) derived from carcinoma-associated fibroblasts (CAFs) on DDP resistance in NSCLC cells. Firstly, NSCLC cells were treated with EVs, followed by detection of cell activity, IC

Indexed as

A549 CellsCancer-Associated FibroblastsCarcinoma, Non-Small-Cell LungCisplatinDrug Resistance, NeoplasmExtracellular VesiclesHumansLung NeoplasmsRNA, Long NoncodingCisplatinRNA, Long NoncodingSNHG12 long non-coding RNA, humancarcinoma-associated fibroblastscisplatin resistantextracellular vesiclesHuRlncrna snhg12Non-small cell lung cancerRNA-binding proteinsRNA stability

Identifiers

PMID35014944
PMCPMC8805932
OpenAlexW4206769360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.